Mazdutide 2026: GLORY-2 Results, DREAMS-3 vs Semaglutide, Dosing Data & Comparison to Tirzepatide

Mazdutide is the first approved GLP-1/glucagon dual agonist. Here is what GLORY-1, GLORY-2 and the DREAMS-3 head-to-head trial show, how it compares to tirzepatide and retatrutide, and its regulatory status.